Global Osteoporosis Therapeutics Market: Market Forecast, Patient Flow,Competitive Landscape, and Pipeline Analysis

Commercial Insights, April 2011, Pages: 110

The Global Osteoporosis therapeutics market was valued at $5.5 billion in 2010, and is expected to reach $5.3 billion by 2018, decreasing at a CAGR of 0.4% between 2010 and 2018. Patent expirations for many leading osteoporosis therapies will result in mass genericizations.

However, factors such as the rising elderly population in all seven top pharmaceutical markets, along with an increasing osteoporosis diagnosis rate and osteoporosis treatment rate, will help to stabilize the declining market. Also, the report foresees a rapid uptake of Forteo/Forsteo and Prolia as one of the significant market events that will offset the declining osteoporosis therapeutics market.

Research Scope:
- Geographies Covered: The US, Germany, France, UK, Spain, Italy, and Japan
- Forecast Period: 8 Years (2010 to 2018)

Market Analysis:
- Osteoporosis therapeutics market size and forecast by geography
- Insights in to market events that impact the osteoporosis therapeutics market by geography
- Leading therapies by geography

Competitive Landscape Analysis:
- Market share insights of leading brands in the global osteoporosis therapeutics market
- Future market share analysis of the global osteoporosis therapeutics market
- Profiles of leading brands by annual therapy cost and their market shares

Patient Flow Analysis:
- Patient flow study with diagnosis rate and treated population rate by geography
- Analysis and forecasts of osteoporosis prevalence population by geography
- Analysis and forecasts of osteoporosis diagnosis population by geography
- Analysis and forecasts of osteoporosis treated population by geography

Unmet Need:
- Unmet need analysis of the global osteoporosis therapeutics market

Pipeline Analysis:
- Analysis of osteoporosis pipeline molecules by phase of development
- Detailed clinical profiles of high potential phase 3 molecules

1 Executive Summary

2 Osteoporosis
2.1 Disease Introduction
2.2 Signs & Symptoms
2.3 Diagnosis
2.4 Treatment

3 Global Osteoporosis Therapeutics Market
3.1 Market Size & Forecast
3.2 Patient Flow Analysis
3.2.1 Epidemiology Analysis
3.2.2 Diagnosis Population Analysis
3.2.3 Treated Population Analysis

4 Geographic Landscape Analysis

5 Current and Future Competition Analysis
5.1 Current Market Share Analysis
5.2 Future Market Share Analysis

5.3 Marketed Therapy Analysis
5.3.1 Reclast/Aclasta
5.3.1.1 Overview
5.3.1.2 Annual Therapy Cost
5.3.1.3 Market Share Analysis
5.3.2 Evista
5.3.2.1 Overview
5.3.2.2 Annual Therapy Cost
5.3.2.3 Market Share Analysis
5.3.3 Forteo/Forsteo
5.3.3.1 Overview
5.3.3.2 Annual Therapy Cost
5.3.3.3 Market Share Analysis
5.3.4 Miacalcin/Miacalcic/Karil
5.3.4.1 Overview
5.3.4.2 Annual Therapy Cost
5.3.4.3 Market Share Analysis
5.3.5 Boniva/Bonviva
5.3.5.1 Overview
5.3.5.2 Annual Therapy Cost
5.3.5.3 Market Share Analysis
5.3.6 Fosamax
5.3.6.1 Overview
5.3.6.2 Annual Therapy Cost
5.3.6.3 Market Share Analysis
5.3.7 Actonel
5.3.7.1 Overview
5.3.7.2 Annual Therapy Cost
5.3.7.3 Market Share Analysis
5.3.8 Prolia
5.3.7.1 Overview
5.3.7.2 Annual Therapy Cost
5.3.7.3 Market Share Analysis

6 Osteoporosis Therapeutics Market in the US
6.1 Market Size & Forecast
6.2 Market Events
6.2.1 Market Drivers
6.2.2 Market Restraints
6.3 Leading Therapies in the US
6.4 Patient Flow Analysis
6.4.1 Epidemiology Analysis
6.4.2 Diagnosis Population Analysis
6.4.3 Treated Population Analysis

7 Osteoporosis Therapeutics Market in Europe
7.1 Market Size & Forecast
7.2 Market Events
7.2.1 Market Drivers
7.2.2 Market Restraints
7.3 Leading Therapies in Europe
7.4 Patient Flow Analysis
7.4.1 Epidemiology Analysis
7.4.2 Diagnosis Population Analysis
7.4.3 Treated Population Analysis

8 Osteoporosis Therapeutics Market in Germany
8.1 Market Size & Forecast
8.2 Patient Flow Analysis
8.2.1 Epidemiology Analysis
8.2.2 Diagnosis Population Analysis
8.2.3 Treated Population Analysis

9 Osteoporosis Therapeutics Market in France
9.1 Market Size & Forecast
9.2 Patient Flow Analysis
9.2.1 Epidemiology Analysis
9.2.2 Diagnosis Population Analysis
9.2.3 Treated Population Analysis

10 Osteoporosis Therapeutics Market in Spain
10.1 Market Size & Forecast
10.2 Patient Flow Analysis
10.2.1 Epidemiology Analysis
10.2.2 Diagnosis Population Analysis
10.2.3 Treated Population Analysis

11 Osteoporosis Therapeutics Market in France
11.1 Market Size & Forecast
11.2 Patient Flow Analysis
11.2.1 Epidemiology Analysis
11.2.2 Diagnosis Population Analysis
11.2.3 Treated Population Analysis

12 Osteoporosis Therapeutics Market IN UK
12.1 Market Size & Forecast
12.2 Patient Flow Analysis
12.2.1 Epidemiology Analysis
12.2.2 Diagnosis Population Analysis
12.2.3 Treated Population Analysis

13 Osteoporosis Therapeutics Market in Japan
13.1 Market Size & Forecast
13.2 Market Events
13.2.1 Market Drivers
13.2.2 Market Restraints
13.3 Leading Therapies IN JAPAN
13.4 Patient Flow Analysis
13.4.1 Epidemiology Analysis
13.4.2 Diagnosis Population Analysis
13.4.3 Treated Population Analysis

14 Unmet Need

15 Osteoporosis Drug Development Pipeline Analysis
15.1 Phase 3 Pipeline Analysis
15.2 Phase 2 Pipeline Analysis
15.3 Phase 1 Pipeline Analysis
15.4 High Potential Therapies
15.4.1 Odanacatib (MK-0822, MK-822)
15.4.1.1 Overview
15.4.1.2 Clinical Studies
15.4.2 SMC021 Oral Calcitonin
15.4.2.1 Overview
15.4.2.2 Clinical Studies
15.4.3 PTH (Preos)
15.4.3.1 Overview
15.4.3.2 Clinicial Studies
15.4.4 Bazedoxifene
15.4.4.1 Overview
15.4.4.2 Clinical Studies

16 Appendix

17 Research Methodology
17.1 Overview
17.2 Data Collection
17.2.1 Secondary Data Collection
17.2.2 Primary Data Collection
17.3 Information Objective
17.4 Research Objective
17.4.1 Market Size Estimation & Forecasting
178.4.2 Analysis
17.5 Data Validation
17.6 Contact Us

List of Tables

Table 1: Osteoporosis Therapeutics Market: Market Forecast, Global, 2010-2018
Table 2: Osteoporosis Therapeutics Market: Disease Prevalence, Global, 2010-2018
Table 3: Osteoporosis Therapeutics Market: Diagnosis Population, Global, 2010-2018
Table 4: Osteoporosis Therapeutics Market: Treated Population, Global, 2010-2018
Table 5: Osteoporosis Therapeutics Market: Leading Therapies, Global, 2010
Table 6: Osteoporosis Therapeutics Market: Leading Therapies, The US, 2018
Table 7: Osteoporosis Therapeutics Market: Market Forecast, The US, 2010-2018
Table 8: Osteoporosis Therapeutics Market: Leading Therapies, The US, 2010
Table 9: Osteoporosis Therapeutics Market: Disease Prevalence, The US, 2010-2018
Table 10: Osteoporosis Therapeutics Market: Diagnosis Population, The US, 2010-2018
Table 11: Osteoporosis Therapeutics Market: Treated Population, The US, 2010-2018
Table 12: Osteoporosis Therapeutics Market: Market Forecast, Europe, 2010-2018
Table 13: Osteoporosis Therapeutics Market: Leading Therapies, Europe, 2010
Table 14: Osteoporosis Therapeutics Market: Disease Prevalence, Europe, 2010-2018
Table 15: Osteoporosis Therapeutics Market: Diagnosis Population, Europe, 2010-2018
Table 16: Osteoporosis Therapeutics Market: Treated Population, Europe, 2010-2018
Table 17: Osteoporosis Therapeutics Market: Market Forecast, Germany, 2010-2018
Table 18: Osteoporosis Therapeutics Market: Disease Prevalence, Germany, 2010-2018
Table 19: Osteoporosis Therapeutics Market: Diagnosis Population, Germany, 2010-2018
Table 20: Osteoporosis Therapeutics Market: Treated Population, Germany, 2010-2018
Table 21: Osteoporosis Therapeutics Market: Market Forecast, France, 2010-2018
Table 22: Osteoporosis Therapeutics Market: Disease Prevalence, France, 2010-2018
Table 23: Osteoporosis Therapeutics Market: Diagnosis Population, France, 2010-2018
Table 24: Osteoporosis Therapeutics Market: Treated Population, France, 2010-2018
Table 25: Osteoporosis Therapeutics Market: Market Forecast, Spain, 2010-2018
Table 26: Osteoporosis Therapeutics Market: Disease Prevalence, Spain 2010-2018
Table 27: Osteoporosis Therapeutics Market: Diagnosis Population, Spain, 2010-2018
Table 28: Osteoporosis Therapeutics Market: Treated Population, Spain, 2010-2018
Table 29: Osteoporosis Therapeutics Market: Market Forecast, Italy, 2010-2018
Table 30: Osteoporosis Therapeutics Market: Disease Prevalence, Italy, 2010-2018
Table 31: Osteoporosis Therapeutics Market: Diagnosis Population, Italy, 2010-2018
Table 32: Osteoporosis Therapeutics Market: Treated Population, Italy, 2010-2018
Table 33: Osteoporosis Therapeutics Market: Market Forecast, UK, 2010-2018
Table 34: Osteoporosis Therapeutics Market: Disease Prevalence, UK, 2010-2018
Table 35: Osteoporosis Therapeutics Market: Diagnosis Population, UK, 2010-2018
Table 36: Osteoporosis Therapeutics Market: Treated Population, UK, 2010-2018
Table 37: Osteoporosis Therapeutics Market: Market Forecast, Japan, 2010-2018
Table 38: Osteoporosis Therapeutics Market: Leading Therapies, Japan, 2010
Table 39: Osteoporosis Therapeutics Market: Disease Prevalence, Japan, 2010-2018
Table 40: Osteoporosis Therapeutics Market: Diagnosis Population, Japan, 2010-2018
Table 41: Osteoporosis Therapeutics Market: Treated Population, Japan, 2010-2018
Table 42: Osteoporosis Therapeutics Market: Phase 3 Pipeline Molecules, 2010
Table 43: Osteoporosis Therapeutics Market: Phase 2 Pipeline Molecules, 2010
Table 44: Osteoporosis Therapeutics Market: Phase 1 Pipeline Molecules, 2010

List of Figures

Figure 1: Osteoporosis Therapeutics Market: Market Forecast, Global, 2010-2018
Figure 2: Osteoporosis Therapeutics Market: Patient Flow, Global, 2010
Figure 3: Osteoporosis Therapeutics Market: Disease Prevalence, Global, 2010-2018
Figure 4: Osteoporosis Therapeutics Market: Diagnosis Population, Global, 2010-2018
Figure 5: Osteoporosis Therapeutics Market: Diagnosis Rate, Global, 2010-2018
Figure 6: Osteoporosis Therapeutics Market: Treated Population, Global, 2010-2018
Figure 7: Osteoporosis Therapeutics Market: Treated Population Rate, Global, 2010-2018
Figure 8: Osteoporosis Therapeutics Market: Geographic Landscape Analysis, 2010
Figure 9: Osteoporosis Therapeutics Market: Geographic Landscape Analysis, 2018
Figure 10: Osteoporosis Therapeutics Market: MARKET SHARE, Global, 2010
Figure 11: Osteoporosis Therapeutics Market: MARKET SHARE, Global, 2010
Figure 12: Osteoporosis Therapeutics Market: Market Forecast, The US, 2010-2018
Figure 13: Osteoporosis Therapeutics Market: Patient Flow, The US, 2010
Figure 14: Osteoporosis Therapeutics Market: Disease Prevalence, The US, 2010-2018
Figure 15: Osteoporosis Therapeutics Market: Diagnosis Population, The US, 2010-2018
Figure 16: Osteoporosis Therapeutics Market: Diagnosis Rate, The US, 2010-2018
Figure 17: Osteoporosis Therapeutics Market: Treated Population, The US, 2010-2018
Figure 18: Osteoporosis Therapeutics Market: Treated Population Rate, The US, 2010-2018
Figure 19: Osteoporosis Therapeutics Market: Market Forecast, Europe, 2010-2018
Figure 20: Osteoporosis Therapeutics Market: Patient Flow, Europe, 2010
Figure 21: Osteoporosis Therapeutics Market: Disease Prevalence, Europe, 2010-2018
Figure 22: Osteoporosis Therapeutics Market: Diagnosis Population, Europe, 2010-2018
Figure 23: Osteoporosis Therapeutics Market: Diagnosis Rate, Europe, 2010-2018
Figure 24: Osteoporosis Therapeutics Market: Treated Population, Europe, 2010-2018
Figure 25: Osteoporosis Therapeutics Market: Treated Population Rate, Europe, 2010-2018
Figure 26: Osteoporosis Therapeutics Market: Market Forecast, Germany, 2010-2018
Figure 27: Osteoporosis Therapeutics Market: Patient Flow, Germany, 2010
Figure 28: Osteoporosis Therapeutics Market: Disease Prevalence, Germany, 2010-2018
Figure 29: Osteoporosis Therapeutics Market: Diagnosis Population, Germany, 2010-2018
Figure 30: Osteoporosis Therapeutics Market: Diagnosis Rate, Germany, 2010-2018
Figure 31: Osteoporosis Therapeutics Market: Treated Population, Germany, 2010-2018
Figure 32: Osteoporosis Therapeutics Market: Treated Population Rate, Germany, 2010-2018
Figure 33: Osteoporosis Therapeutics Market: Market Forecast, France, 2010-2018
Figure 34: Osteoporosis Therapeutics Market: Patient Flow, France, 2010
Figure 35: Osteoporosis Therapeutics Market: Disease Prevalence, France, 2010-2018
Figure 36: Osteoporosis Therapeutics Market: Diagnosis Population, France, 2010-2018
Figure 37: Osteoporosis Therapeutics Market: Diagnosis Rate, France, 2010-2018
Figure 38: Osteoporosis Therapeutics Market: Treated Population, France, 2010-2018
Figure 39: Osteoporosis Therapeutics Market: Treated Population Rate, France, 2010-2018
Figure 40: Osteoporosis Therapeutics Market: Market Forecast, Spain, 2010-2018
Figure 41: Osteoporosis Therapeutics Market: Patient Flow, Spain, 2010
Figure 42: Osteoporosis Therapeutics Market: Disease Prevalence, Spain, 2010-2018
Figure 43: Osteoporosis Therapeutics Market: Diagnosis Population, Spain, 2010-2018
Figure 44: Osteoporosis Therapeutics Market: Diagnosis Rate, Spain, 2010-2018
Figure 45: Osteoporosis Therapeutics Market: Treated Population, Spain, 2010-2018
Figure 46: Osteoporosis Therapeutics Market: Treated Population Rate, Spain, 2010-2018
Figure 47: Osteoporosis Therapeutics Market: Market Forecast, Italy, 2010-2018
Figure 48: Osteoporosis Therapeutics Market: Patient Flow, Italy, 2010
Figure 49: Osteoporosis Therapeutics Market: Disease Prevalence, Italy, 2010-2018 68
Figure 50: Osteoporosis Therapeutics Market: Diagnosis Population, Italy, 2010-2018
Figure 51: Osteoporosis Therapeutics Market: Diagnosis Rate, Italy, 2010-2018
Figure 52: Osteoporosis Therapeutics Market: Treated Population, Italy, 2010-2018
Figure 53: Osteoporosis Therapeutics Market: Treated Population Rate, Italy, 2010-2018
Figure 54: Osteoporosis Therapeutics Market: Market Forecast, UK, 2010-2018
Figure 55: Osteoporosis Therapeutics Market: Patient Flow, UK, 2010
Figure 56: Osteoporosis Therapeutics Market: Disease Prevalence, UK, 2010-2018
Figure 57: Osteoporosis Therapeutics Market: Diagnosis Population, UK, 2010-2018
Figure 58: Osteoporosis Therapeutics Market: Diagnosis Rate, UK, 2010-2018
Figure 59: Osteoporosis Therapeutics Market: Treated Population, UK, 2010-2018
Figure 60: Osteoporosis Therapeutics Market: Treated Population Rate, UK, 2010-2018
Figure 61: Osteoporosis Therapeutics Market: Market Forecast, Japan, 2010-2018
Figure 62: Osteoporosis Therapeutics Market: Patient Flow, Japan, 2010
Figure 63: Osteoporosis Therapeutics Market: Disease Prevalence, Japan, 2010-2018
Figure 64: Osteoporosis Therapeutics Market: Diagnosis Population, Japan, 2010-2018
Figure 65: Osteoporosis Therapeutics Market: Diagnosis Rate, Japan, 2010-2018
Figure 66: Osteoporosis Therapeutics Market: Treated Population, Japan, 2010-2018
Figure 67: Osteoporosis Therapeutics Market: Treated Population Rate, Japan, 2010-2018
Figure 68: Osteoporosis Therapeutics Market: Drug Pipeline by Clinical Trial Phase, Global, 2010

- Ablynx
- Abbott Laboratories
- Acceleron Pharma
- Acologix
- Akzo Nobel
- Alcon
- Allergan
- Amgen
- Astellas Pharma
- Astellas Pharma
- AstraZeneca
- Bausch & Lomb
- Baxter International
- Bayer
- Biogen Idec
- Boehringer Ingelheim
- Bone Medical Limited
- Bristol-Myers Squibb
- Cephalon
- Chiesi Farmaceutici SpA
- Chugai Pharmaceutical
- Chugai Pharmaceutical Co.
- CSL
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Dong Wha Pharma Co/P&G Pharma/Teijin Pharma
- Eisai
- Eli Lilly and Company
- Ente Ospedaliero Ospedali Galliera
- Forest Laboratories
- Genentech
- Genta Incorporated
- Genzyme
- Gilead Sciences
- GlaxoSmithKline
- GlaxoSmithKline
- H. Lundbeck
- Hoffmann–La Roche
- King Pharmaceuticals
- Kyowa Hakko
- MDRNA
- Merck & Co
- Merrion Pharmaceuticals
- Mitsubishi Pharma
- Mylan Laboratories
- Novartis
- Novo Nordisk
- Nycomed Limited
- Ono Pharmaceutical Co.
- Osteologix
- Pantarhei Bioscience
- Pfizer
- PhytoHealth Corporation
- Procter & Gamble
- Radius Health
- Sanofi-Aventis
- Shionogi
- Shire
- SINOPHARM
- Solvay
- Taiho Pharmaceutical Co.
- Takeda Pharmaceutical Co.
- Tarsa Therapeutics Inc.
- Teva Pharmaceutical Industries
- UCB
- Unigene Laboratories
- Velcura Therapeutics
- Watson Pharmaceuticals
- Wyeth

Products Mentioned:

- AAE581
- AC-100
- ACE-011
- Actonel
- ALX 0141
- AMG 785
- ATF936
- AXT914
- BA058
- Boniva/Bonviva
- Capsitonin
- CHF4227
- Denosumab + Alendronate
- DW-1350
- Estetrol
- Evista
- EX101
- Forteo/Forsteo
- Fosamax
- G4544(a)
- JTT-305
- MER-103
- Miacalcin/Miacalcic/Karil
- MK-5442
- NB S101
- Neridronate
- Odanacatib
- ONO-5334
- PHN031
- Prolia
- PTH analogs oral
- Reclast/Aclasta
- Relacatib
- RG484
- rhBMP-2 + CPM
- sCT nasal
- sCT oral
- SMC021 Oral calcitonin
- Teriparatide
- VEL-0230
- YM529
- ZP-PTH
- ZT-031
- ZT-034

Product Samples

A sample for this product is available. Please Login/Register to download this sample.

Customers who bought this item also bought

• Medical Nutrition - A Global Market Overview
• Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014
• Disinfectants - Global Strategic Business Report
• Proteomics - Global Strategic Business Report
• Gene Amplification Technologies - Global Strategic Business Report
• Molecular Diagnostics - Global Strategic Business Report
• Biophotonics - Global Strategic Business Report
• Diabetes Diagnostics - Global Strategic Business Report
• Moist Wound Dressings Markets Worldwide
• Market and Product Forecast: Osteoporosis - Prolia and odanacatib to restore growth in the market